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Purpose: To report on the commissioning and clinical validation of the first com-
mercially available independent Monte Carlo (MC) three-dimensional (3D) dose cal-
culation for CyberKnife robotic radiosurgery system® (Accuray, Sunnyvale, CA).
Methods: The independent dose calculation (IDC) by SciMoCa® (Scientific RT,
Munich, Germany) was validated based on water measurements of output factors
and dose profiles (unshielded diode, field-size dependent corrections). A set of 84
patient-specific quality assurance (QA) measurements for multi-leaf collimator (MLC)
plans, using an Octavius two-dimensional SRS1000 array (PTW, Freiburg, Germany),
was compared to results of respective calculations. Statistical process control (SPC)
was used to detect plans outside action levels.
Results: Of all output factors for the three collimator systems of the CyberKnife,
99% agreed within 2% and 81% within 1%, with a maximum deviation of 3.2% for a
5-mm fixed cone. The profiles were compared using a one-dimensional gamma eval-
uation with 2% dose difference and 0.5 mm distance-to-agreement (Γ(2,0.5)). The
off-centre ratios showed an average pass rate >99% (92–100%). The agreement of
the depth dose profiles depended on field size, with lowest pass rates for the small-
est MLC field sizes. The average depth dose pass rate was 88% (35–99%). The IDCs
showed a Γ(2,1) pass rate of 98%. Statistical process control detected six plans out-
side tolerance levels in the measurements, all of which could be attributed the mea-
surement setup. Independent dose calculations showed problems in five plans, all
due to differences in the algorithm between TPS and IDC. Based on these results
changes were made in the class solution for treatment plans.
Conclusion: The first commercially available MC 3D dose IDC was successfully
commissioned and validated for the CyberKnife and replaced all routine patient-
specific QA measurements in our clinic.
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1 | INTRODUCTION
To ensure safe dose delivery in stereotactic radiotherapy, uncertain-
ties and errors in dose delivery must be minimized by an extended
and strict quality assurance (QA) protocol. An established part of a
QA protocol is the patient-specific pre-treatment verification of the
calculated dose, either by measurements or by checking the monitor
units with an independent dose calculation (IDC).1
Patient-specific QA measurements can be performed using
chambers, film, or diode arrays.2–7 Especially for stereotactic
CyberKnife treatment plans, both measurement equipment and
analysis require stringent quality criteria. Internationally acknowl-
edged gamma criteria of 2% dose difference and 2 mm distance-
to-agreement Γ(2,2) are insufficient to detect possible errors rele-
vant during CyberKnife dose delivery.2,4,8 However, measurements
are costly by consuming valuable personnel and machine time.
Besides this, despite fulfilling the strict criteria, the relevant errors
that can be picked up are limited and mainly refer to problems
regarding the delivery system.9–11 It is more efficient that these
types of issues are addressed by proper commissioning and
machine QA.8
An alternative to pre-treatment measurements is an IDC.1,8 This
method recalculates the dose independent of a vendor treatment
planning system (TPS), based on the treatment plan parameters for
the given plan, and can range between a point dose calculation to a
full three-dimensional (3D) Monte Carlo calculation.12–14 Indepen-
dent dose calculation platforms have been developed for the Cyber-
Knife fixed cone and Iris™ collimators15,16 and recently also for the
newly developed MLC collimator.17,18 None of these solutions offers
a (MC) 3D IDC that is commercially available.
This paper describes the commissioning and clinical implementa-
tion of the first commercially available 3D Monte Carlo dose engine
(SciMoCa RT, Munich) for two CyberKnife® M6™ robotic radio-
surgery system (Accuray Inc., Sunnyvale, CA) in order to replace
patient-specific QA measurements. To this end, the beam model pro-
vided by SciMoCa was compared to water tank reference measure-
ments for all three collimator sets. Using SPC, treatment plans
outside tolerances were detected in array measurements and IDCs
and were further analysed. As the vast majority of our patient cohort
is treated using the MLC collimator, retrospectively a set of 84
patient MLC plans was used for this evaluation.
2 | MATERIALS AND METHODS
2.A | Modeling of the CyberKnife accelerators
The SciMoCa algorithm has been described in Ref. [26] for general
purpose linear accelerators with MLC. The CyberKnife implementa-
tion uses the same patient/phantom transport code, but differs in
source and collimator models. The latter are purpose-built for fixed
cones and Iris, whereas the MLC model was adapted from the model
described in Ref. [26] with respect to transmission, leakage, and
additional fixed collimation elements in the assembly. The source
model is comprised of four virtual sources (primary, primary collima-
tor and other head scatter, beam filter scatter, contamination elec-
trons), whereby the scatter components amount to only about 3.3%
of total energy fluence at the maximum field size of the MLC, and
about 1.7% for the 60 mm cone.
The three beam models (one for each collimator type) of a
CyberKnife M6 share the same source model, which was derived
from water phantom depth dose curve (DDC) and output factor (OF)
measurements obtained with the Incise2 MLC. Input for the models
was identical to the data obtained during CyberKnife commissioning:
a DDC, a set of off center ratios (depth 15, 50, 100, 200, and
300 mm) and an OF for each field size summarized in Table 1. For
the MLC cross profiles were included. Reference depth for all colli-
mators and field sizes was 1.5 cm.
Input DDCs and OFs for the fixed cones and Iris fields were
used for validation. All measurements were performed with a PTW
60012 unshielded diode in a PTW MP3 tank. Measurements were
corrected for small field detector response using correction factors
as published by Francescon et al.19,20 Diameters of circular cones
were calibrated from cross-profiles to account for manufacturing
tolerances in the order of 0.05 mm. The maximum energy of both
machines differed by 100 keV and the electron spot radius by
0.08 mm.
2.B | Commissioning
2.B.1 | Beam model validation
To validate the six individual beam models of the two CyberKnife
systems, calculated OFs, DDCs, and off-center ratios (OCRs) were
compared to corresponding measurements for a range of field sizes
(Table 1). OFs were calculated using a voxel size of 1 × 1 × 1 mm3
for fields ≤ 35 mm (fixed and Iris) or 30.8 × 30.8 mm2 (MLC) and
1.8 × 1 × 1.8 mm3 for larger fields with a statistical uncertainty of
0.1%. The statistical uncertainty is defined as the mean uncertainty
of all voxels with dose >70% of the max dose, computed from 64
batches simulated with different random seeds. Depth dose curves
were calculated with a voxel size of 1 × 1 × 1 mm3 for fields ≤ 30.8
× 30.8 mm2 and 1.8 × 1 × 1 mm3 for larger fields. OCRs were cal-
culated with a voxel size of 0.5 × 1 × 0.5 mm3 for fields ≤ 15.4 ×
15.4 mm2 and 1 × 2 × 1 mm3 for larger fields. These calculations
had 0.25% statistical uncertainty. Comparisons between calculations
and measurements were based on a 1D gamma evaluation, using
Γ(1,0.5) and Γ(2,0.5), respectively.21 Analysis included the build-up
region.
2.B.2 | Independent dose calculation of clinical
plans using SciMoCa
SciMoCa was used to retrospectively recalculate a set of 84 patient
plans (35 and 49 on CyberKnife 1 and 2), using 1.5 mm3 resolution
and 0.5% statistical uncertainty. The two systems are dosimetrically
similar, but require different beam models in the TPS. In practice
these models produce identical plans. All plans were
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hypofractionated and generated using the MLC in combination with
the finite size pencil beam (FSPB) algorithm, the only available at
the time, using the voxel size of the planning CT (resolution in
plane 1 × 1 mm, slice thickness depending on the treatment site
1–2 mm). Treatment sites ranged from pancreas (21), liver (16),
H&N (15) and prostate (4), to oligometastases (25) with a PTV size
ranging between 30 and 300 cc. Clinical plans were generated
using Multiplan® (version 5.1.3). Dose comparison was performed
using an in-house developed software platform for 3D gamma eval-
uation Γ(2,1), using global maximum, and 10% dose cutoff. The Sci-
MoCa algorithm assigns material properties according to mass
density, using ICRU tabulated values. For example, a voxel with
density 1.45 g cm−3 would be interpreted as “ICRU bone with den-
sity 1.45,” and similar for lung for voxels with density between
0.75 and 0.011 g cm−3.
2.B.3 | Establishing action levels
For every new QA method, appropriate action levels need to be
established to identify differences between dose calculated by the
TPS and delivered dose. Action levels for IDCs were determined
using statistical process control (SPC).22 This method has been
described previously for radiotherapy quality assurance, such as linac
QA,23 image-guidance QA,24 IMRT dose verification25 and similar to
our application, independent monitor unit calculation26 and the
replacement of patient-specific QA measurements by IDCs.27 Using
SPC, chronological processes such as patient-specific QA can be
evaluated in control charts that show how the process randomly var-
ies over time. Control charts typically show a central average line
and statistically determined upper and lower control limits. In control
charts, in contrast to the general conception in radiotherapy, system-
atic errors are defined as points outside the action levels. Besides
systematic errors, the charts will show if the average or the random
variation changes due to alterations in the treatment process. To set
action levels in CyberKnife plan QA, two charts were used; an aver-
age chart, displaying the average and random spread of the measure-
ments and a range chart that displays the difference between
successive measurements and their average value. The range R was
calculated according to Eq. (1).
Ri ¼ xixi1j j (1)
where x represents an individual, successive QA measurements. This
leads to the following equations for the center lines and upper and





















The factors d2 and d3 are tabulated and are valid for a subgroup
size of n¼2 where each measurement can be treated as an indepen-
dent data point.23,28 In this case Rl will be effectively set to 0.
2.C | Comparison to pre-treatment measurements
The intended use of the SciMoCa IDCs is to replace patient-specific
QA measurements. To ensure that this can be safely done, a risk
assessment of the QA program, in line with AAPM TG100, needs to
take place. As part of this, for the same set of 84 patients that
received an IDC, individual pre-treatment measurements were re-
evaluated using the SPC method. Identical gamma criteria as in IDCs
were used: Γ(2,1), using the global maximum, and a 10% dose cutoff.
Plans outside the action levels were further analyzed.
2.C.1 | Measurements of QA plans
The clinical Incise2 MLC-based FSPB treatment plans of 84 patients,
were matched with and recalculated on the CT scan of an Octavius
1000SRS (PTW, Germany) array embedded in a solid water slab
phantom using the workflow offered by the Multiplan software. For
all plans a two-dimensional (2D) coronal dose plane was exported at
the height in the phantom corresponding to the measurement plane
in the array. Due to the angular dependence of the SRS1000 array,
all beams were delivered with the linac head perpendicular to the
phantom surface.29
This detector array consist of 977 MicroLion liquid-filled ioniza-
tion chambers. The spacing between the chambers in the high-
TAB L E 1 CyberKnife field sizes. X-axis in leaf travel direction, Y-axis perpendicular to it.
Field size
Fixed/Iris (mm) 5 7.5 10 12.5 15 20 25 30 35 40 50 60
MLC X (mm) 7.6 15.4 23.0 30.8 38.4 46.2 53.8 69.2 84.6 100.0 115.0
MLC Y (mm) 7.7 15.4 23.1 30.8 38.4 46.2 53.9 69.3 84.7 100.1 100.1
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resolution area (5.5 × 5.5 cm2) is 2.5 mm. In the low resolution area,
filling the remainder of the 11 × 11 cm2 area, the distance between
the chambers is 5 mm. The use of the 1000SRS array for the Cyber-
Knife has been investigated and found sufficiently accurate for
patient-specific QA measurements.4,6 Our 1000SRS array has a fixed
geometry with a slab phantom in which a set of three fiducial mark-
ers are embedded. Pre-treatment alignment on the CyberKnife is
based on a fiducial match between two stereoscopic x-ray images
with digitally reconstructed radiographs based on the treatment
planning CT, ensuring optimal alignment between planned and deliv-
ered geometry.
A 2D gamma analysis was performed in Verisoft (v 7.0, PTW, Frei-
burg, Germany) for the two CyberKnife systems separately. No addi-
tional geometrical shift of the dose planes, to obtain optimal pass
rates, was allowed in the analysis to prevent biased gamma results.
3 | RESULTS
3.A | Validation of the beam models
Absolute DDCs and OFs, and relative cross profiles calculated by
SciMoCa were compared to measurements in a homogenous water
phantom using a Γ(2,0.5) and Γ(1,0.5), respectively.18 Figure 1 shows
measured versus calculated dose profiles (crossplane) and depth
curves for increasing fields sizes of the Incise2 MLC.
Of the calculated OF for both CyberKnife systems 99% agreed
within 2% and 81% within 1%, the maximum deviation of 3.2% is
associated with a cone size of 5 mm (Table 2).
Table 3 summarizes the comparison between the measurements
and calculations. The off-centre ratios showed an average pass rate
>99% (92–100%) using Γ(1,0.5). The average depth dose pass rate
was 88% (35–99%), where the agreement strongly depended on field
size. The lowest pass rates were associated with the smallest MLC
field sizes. DDCs were compared in terms of absolute dose. A differ-
ence in the OF propagates to a global difference in the DDC.
3.B | Clinical validation
3.B.1 | Establishment of action levels
Table 4 shows a summary of the SPC using average and Range
charts that are displayed in Fig. 2. The mean pass rate of the mea-
surements was 89% (range 49–100%) and 97% (range 89–100%) for
the two CyberKnife systems. The mean pass rate of the IDCs was
98% (range 88–100%).
F I G . 1 . [Left] Measured (solid lines) and calculated (crosses) off-axis beam profiles of increasing field sizes of the Incise2 collimator. [Right]
Measured (solid lines) and calculated (crosses) depth dose curves of increasing field sizes of the Incise2 collimator. Field sizes: 7.6 × 7.7 mm2
(blue), 15.4 × 15.4 mm2 (green), 23.0 × 23.1 mm2 (magenta), 38.4 × 38.4 mm2 (cyan), 69.2 × 69.3 mm2 (red), 100 × 100.1 mm2 (black).
TAB L E 2 Comparison of measured and calculated OF for two CyberKnife systems.
CyberKnife 1 CyberKnife 2
Fixed Iris MLC Fixed Iris MLC














Within 1% 9/12 10/12 10/11 7/12 11/12 10/11
Within 2% 12/12 12/12 11/11 10/12 12/12 11/11
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3.B.2 | Plans exceeding the action levels
Table 4 and Fig. 2 show several plans that exceed the action levels:
systematic errors. A single, unique patient plan could cause up to
four systematic errors if it exceeds the control levels in all four
control charts used in this analysis. In the measurements, six
unique plans failed. These systematic errors could, after further
analysis not be attributed to problems in treatment planning. In the
IDCs five unique plans were outside the action levels. One plan
exceeded the action levels in all four control charts. The systematic
errors from the IDC have different origins, as detailed in the dis-
cussion.
3.B.3 | Comparison of IDCs and measurements
One plan exceeded the action levels in both the measurements and
IDCs. However, none of the other systematic errors in the IDCs
appeared in the analysis of the measurements and vice versa. The
Pearson correlation coefficient between measurements and IDCs for
the gamma pass rate and gamma mean ranges between −0.3 and
0.5.
4 | DISCUSSION
The first commercially available independent 3D MC IDC algorithm
for all three collimator types of the CyberKnife was developed by
Scientific RT on initiative of the Erasmus MC and validated together.
The calculations showed excellent agreement with measurements in
a homogeneous water phantom using very strict evaluation criteria
of Γ(2,0.5). Including the build-up region and all three collimators up
to the smallest field size of 5 mm, 88% of the calculated and mea-
sured points passed Γ(2,0.5), excluding the smallest field sizes < 2 ×
2 cm this value increased to 93%. The largest deviations in DDC
occurred for the smallest MLC fields. Our results are comparable to
previous work on in-house developed IDCs.15–18
The agreement in dose calculated by Multiplan and SciMoCa is
very high. The average gamma pass rate Γ(2,1) 98% and mean 0.27
found in this work for 3D IDCs are well above the advised numbers
of AAPM TG 135 of Γ(2,2) ≥ 90%.8 The pass rates agree well with
earlier work on CyberKnife patient-specific QA.2,15,17,18 Previously,
similarly high agreement between Acuros and SciMoCa calculated
dose distributions had been reported.30
TAB L E 3 Pass rates from the comparison between water tank validation measurements and calculations by SciMoCa for two CyberKnife
systems.
CyberKnife 1 CyberKnife 2
Fixed Iris MLC Fixed Iris MLC
DTA = 0.5
DD ≤ 1%
OCR 100 100 100 (98–100) 100 100 99 (92–100)
DDC 63 (10–97) 84 (43–93) 70 (5–99) 77 (35–91) 81 (58–91) 59 (3–93)
DTA = 0.5
DD ≤ 2%
OCR 100 100 100 (99–100) 100 100 100 (98–100)
DDC 79 (35–99) 92 (87–93) 90 (36–99) 91 (85–92) 89 (75–93) 81 (25–93)
TAB L E 4 Results of two-dimensional (2D) gamma analysis of
measured versus TPS dose on CyberKnife 1 and 2 and of the three-
dimensional (3D) gamma analysis of IDC vs TPS dose. Γ(2,1), dose











Acpass(%) 89 97 98
Aupassa 100 100 100




Acmean 0.55 0.46 0.27
Aumean 0.89 0.59 0.36






Rcpass(%) 10 2 2
Rcmean 0.18 0.07 0.05
Rupass(%) 33 7 4











6 (3) 3 (3) 13
(5)
aMore than 100%.
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The pass rates of the pre-treatment measurements show a
strong learning curve associated with the in-house development of a
dedicated phantom. The gamma pass rate increased from 89%, for
the initial set of measurements on CyberKnife system 1, to 97% for
the subsequent set on system 2 coinciding with the change to the
dedicated phantom. Similarly, the gamma mean decreased from 0.55
to 0.46. SPC is a valuable tool to visualize these trends in QA. The
gamma pass rates in this study exceed those of similar work.2–4,6
This can be attributed to the use of a dedicated CyberKnife QA
phantom and the beam delivery perpendicular to the array surface,
to avoid angular correction of the array response.
Action levels for gamma pass rate and gamma mean were set
using SPC. Plans exceeding the action levels were further analyzed.
In the measurements 5 out of 6 systematic errors could be explained
by a scaling factor in the dose attributable to the initial absence of a
dedicated phantom. The fourth case corresponds to a plan with a
large target volume, due to which the high dose gradients over-
lapped with the low resolution region of the diode array. Hence,
none of these systematic errors could be attributed to either
machine or TPS quality issues. The origins of the five plans causing
systematic errors in the IDCs are diverse. The target in the plan that
exceeded the threshold in all four charts was located very close to
the surface, in the buildup region. Larger deviations between algo-
rithms can be expected for these type of plans. In clinical practice
we have since seen more deviations in IDCs for superficial targets. A
second plan outside tolerance showed a dose difference at the inter-
face between soft tissue and bone. The clinical impact of this effect
was limited as the dose constraints and the coverage were met using
both algorithms. The remaining three cases were boost plans for the
head and neck region. In general the presence of air close to the tar-
get is limited in these plans. In the three cases outside the toler-
ances, of sixteen head and neck cases analyzed in total, the
unclipped PTV extended in air. Recalculation of these five plans with
the MC algorithm, now available for MLC, improved the agreement
in dose except for the first case. Based upon these results changes
have been made in our class solutions.
The correlation between gamma parameters for patient-specific
QA measurements and IDCs was low with a Pearson correlation
coefficient for the gamma pass rate and gamma mean ranging
between −0.3 and 0.5. While the IDC was able to detect clinically
relevant problems in the treatment plans, the measurements only
























































Range Chart: mean gamma
F I G . 2 . Gamma analysis of the comparison between IDCs and TPS. Average and range charts for gamma pass rate and mean gamma.
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a systematic error in both IDC and measurements seems a coinci-
dence, as the origin of the deviation was different. Based on these
results and an extensive period of testing the MLC,31 we have
replaced our patient-specific QA measurements by IDCs. Such a
change in the QA program should be accompanied by a risk analysis
in line with AAPM TG100. Issues that previously might have been
intercepted only during patient-specific QA measurements, must be
picked up during machine QA. In our institute we work with class
solutions for treatment sites. When introducing a new treatment site
or plan technique a set of measurements is performed to validate
the deliverability before relying on IDCs only. Plans outside protocol
or class solution always receive a pre-treatment measurement. End-
to-end tests are performed when changes, such as a new TPS ver-
sion, are introduced in the clinical practice. Upon replacement of the
pre-treatment measurements by IDCs a set of plans reflecting the
clinical population was added to our QA program.
In this study, we focused on gamma parameters, however, the
IDC method also allows us to look at clinically relevant differences
in DVHs parameters. This is often used in our clinical practice and is
a valuable additional tool to detect issues in treatment planning.32
Also, potential future development of log file analysis could further
boost the confidence in the actual delivered dose, bridging the gap
between machine QA and machine settings during dose deliv-
ery.33,34
5 | CONCLUSION
Commercially available 3D Monte Carlo IDC software was success-
fully commissioned and validated. Good agreement was observed
between the dose calculation algorithms provided by the Multiplan
TPS and SciMoCa based on reference measurements in water. The
use of the IDC in clinical practice has been validated by analyzing a
set of 84 patient plans using SPC and a comparison to pre-treatment
measurements. After a risk assessment of our QA program, indepen-
dent dose calculations using SciMoCa have replaced regular patient-
specific QA measurements for the CyberKnife in our institute.
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